Silexion Therapeutics
Illinois City
About Silexion Therapeutics
Silexion Therapeutics is a biotechnology company that focuses on developing treatments for KRAS-driven cancers. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy in an extended-release formulation for the treatment of locally advanced pancreatic cancer. Silexion offers its clinical-stage oncology platform with plans for further trials to improve treatment outcomes for patients with specific KRAS mutations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $12.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:SLXN
- Website: silexion.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/silexion-therapeutics-43247 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.